Answers are grounded in this paper and cite their sources.
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasingly recognized as a multisystem condition with extrahepatic complications, including cognitive decline, Alzheimer's disease, and related dementias. However, conventional clinical tools have limited ability to predict dementia-related mortality in this population. Objective To develop and internally validate survival-based machine-learning models for predicting dementia-related mortality among adults with MASLD and identify key clinical predictors. Methods Adults with MASLD were identified from NHANES III with linked mortality data. Dementia-related mortality was defined using National Death Index codes for Alzheimer's disease and other dementias. Cox proportional hazards models, random survival forests, gradient-boosted survival models, and logistic regression were developed and compared with exploratory comparator model. Performance was evaluated using concordance indices, area under the receiver-operating-characteristic curve, Brier scores, and reclassification metrics relative to the FIB-4 score. Results Among 1774 adults with MASLD, 115 dementia-related deaths occurred during a median follow-up of 193 months. Overall discrimination was modest. Logistic regression showed the highest discrimination in 5-fold cross-validation, whereas the penalized Cox model achieved the highest bootstrap C-index. The gradient-boosted survival model demonstrated the greatest improvement in reclassification compared with FIB-4. Exploratory risk stratification classified all dementia-related deaths within the high-risk cohort, although these findings warrant cautious interpretation due to possible overfitting. Waist circumference, diabetes, body mass index, and age were the most influential predictors. Conclusions Survival-based models may improve identification of MASLD patients at elevated risk of dementia-related mortality. Metabolic and anthropometric factors appeared more informative than liver fibrosis scores, and warrant external validation in contemporary cohorts.
No takes yet. Share an insight, caveat, or question.
Njei et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: